Again, we can bet how much money they can raise, whether it will be enough by December or the end of the year, to complete a BLA or merger. It may be best to merge with a company that has enough money to bring Leronlimab to the market, that way they would come to NASDAQ and with this kind of drug that is in the BLA completion phase and with so many indications, the funds would be secured.